Zilucoplan
As of the edition of 20 October 2026, Zilucoplan is a protein: marketed, first approved in 2023 (JP); acts on C5.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2023
- Kind
- Protein
- Brand name
- Zilbrysq
- First approved
- 25 September 2023 (JP)
- Approvals on record
- 5 in 3 regions
- Holder of the most recent approval
- UCB; 3 holders in all
- Registered trials
- 17, 2 stopped early
- Disease areas
- Nervous system; Cancer; Immune system; Blood and lymph; Nutrition and metabolism; Infections
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Zilucoplan.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| C5 | Complement C5 | P01031 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 1 | 1 | 0 |
| Phase 2 | 5 | 3 | 0 | 2 |
| Phase 3 | 10 | 6 | 4 | 0 |
| All trials | 17 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| UCB | Applicant and Lead sponsor of trials | 2017 to now |